Professor John Thompson awarded prestigious 2018 RPA Foundation Research Medal
31 August 2018
Former Executive Director of Melanoma Institute Australia Professor John Thompson has been awarded the prestigious 2018 RPA Foundation Research Medal for his outstanding contribution to melanoma treatment and research.
“I've won some medals in my time but this is undoubtedly the high point,” he said. Professor Thompson's illustrious career included 18 years at the helm of the former Sydney Melanoma Unit and now MIA, changing the face of melanoma treatment around the world. He most recently chaired the Working Group leading the updating of the Melanoma Clinical Care Guidelines.
Professor Thompson is only the second surgeon to take out the award. He was instrumental in the development, description, and refinement of the isolated limb infusion technique for patients with advanced limb cancers. He has made an enormous contribution to advances in melanoma treatment and has influenced breakthrough developments in the melanoma landscape.
For RPA’s Director of Research, Warwick Britton, Professor Thompson has been a game changer.
"His approach has changed the paradigm of management of melanoma surgery.”
Can an individual’s risk factors for melanoma be used to tailor skin self-examinations and surveillance programs?
Prof Georgina Long has been appointed President-Elect Society for Melanoma Research (SMR).
The Australasian Melanoma Conference is bringing together some of the world's leading researchers and clinicians.
Best practice guidelines for melanoma care have gone digital with the first-ever online guidelines developed to adapt to the rapid change in clinical management.
Congratulations are in order for two of our talented researchers.
Professor Richard Scolyer will be sharing his expertise on melanoma pathology at the upcoming Australasian Melanoma Conference. Here he discusses what he'll be presenting on.
Researchers at MIA have established a High Risk Clinic to monitor people at very high risk of developing melanoma.
A generous donation has enabled a medical oncologist from Portugal to learn from the best in the world at MIA.
MIA is hosting a conference to bring together greats minds in melanoma research that will make a difference to the lives of melanoma patients
Meet Michelle, our Translational Research Officer whose role is to connect the clinics to the lab by ensuring patient blood and tissue samples are documented and carefully stored in our BioSpecimen Bank.
Dr James Wilmott says his Wildfire Award will help expand research into treatment options for people with mucosal melanoma, a rare but deadly form of skin cancer.
Following the recent hype around immunotherapies in cancer, CEO Carole Renouf shares the greatest story never told… resistance… and what MIA is doing to address it.
A/Prof Wargo discusses the research she will be presenting as a keynote speaker at the upcoming Australasian Melanoma Conference.
Dr James Wilmott has been awarded the Wildfire award at this year's Cancer Institute NSW's Premier Awards for Outstanding Cancer Research.
The community has responded generously to our recent appeal to fund a specialised nursing position in an exciting new clinical trial.
We have developed a unique clinical trial that will use existing drugs to target rare genes in melanoma patients.
Data presented at the recent ASCO Annual Meeting showcased advances in melanoma research, particularly long-term survival data.
We value your privacy and want you to be familiar with how we collect, use and disclose your information.
Melanoma Institute Australia has partnered with IBM Research in Australia to help further advance melanoma identification using cognitive technology.
CEO Carole Renouf chats to senior clinicians and researchers as part of our "4 Questions With..." short video series.